Ranibizumab is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment directed against human vascular endothelial growth factor A (VEGF-A), which is a glycoprotein implicated in the pathophysiology of age-related macular degeneration. Ranibizumab is used to treat various ocular disorders with abnormal growth of blood vessels, such as neovascular (wet) age-related macular degeneration. The development of ranibizumab first began after bevacizumab, another anti-VEGF anticancer drug, was discovered to inhibit neovascularization and used in the off-label treatment of neovascular age-related macular degeneration for intravenous injection. In order to improve drug delivery to the target organ, ranibizumab is available for intravitreal use.
Ranibizumab was initially approved by the FDA in 2006 and by the European Commission (EC) in 2007. It is marketed under the brand names LUCENTIS and SUSVIMO. BYOOVIZ, a biosimilar of LUCENTIS, was approved by Health Canada in March 2022, making it the first and only biosimilar drug of ranibizumab available in Canada. In August 2022, other biosimilars CIMERLI and RAIVISIO were approved by the FDA and EC, respectively.
Ranibizumab injection for intravitreal use is indicated to treat Neovascular (wet) Age-related Macular Degeneration (AMD), macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization.
Ranibizumab injection for for intravitreal use via ocular implant is used to treat Neovascular (wet) Age-related Macular Degeneration (AMD) in patients who have responded to at least two intravitreal injections of a VEGF inhibitor.
Spedali Civili di Brescia, Brescia, BS, Italy
Klinik für Augenheilkunde, Klinikum Chemnitz gGmbH, Chemnitz, Germany
Dept of Ophthalmology - UNIFESP/Hospital São Paulo, São Paulo, SP, Brazil
Scientific and Research Institute named after Helmholtz, Moscow, Russian Federation
Regional Clinical Ophthalmic Hospital named TI Yeroshevsky, Samara, Russian Federation
Hospital dos Olhos do Paraná, Curitiba, Paraná, Brazil
Novartis Investigative Site, Napoli, Italy
Retinal Diagnostic Center, Campbell, California, United States
Southern California Desert Retina Consultants, Palm Desert, California, United States
American Institute of Research (Administrative Only), Whittier, California, United States
Novartis Investigative Site, Pozzuoli, Italy
Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, United States
Cole Eye Institute at Hillcrest Hospital, Mayfield Heights, Ohio, United States
Novartis Investigative Site, Nedlands, Western Australia, Australia
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.